Document is current
Any future updates will be listed below
-
Authors
Kumar, Arni https://orcid.org/0000-0002-3326-2141
Singh, Arin
Reljic, Tea https://orcid.org/0000-0003-2029-6753
Iqbal, Madiha https://orcid.org/0000-0001-6752-5440
Mohty, Razan https://orcid.org/0000-0002-0189-8233
Murthy, Hemant https://orcid.org/0000-0003-4534-4248
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Parrondo, Ricardo https://orcid.org/0000-0002-9314-9933
Ayala, Ernesto
Roy, Vivek https://orcid.org/0000-0002-5950-4620
Aljurf, Mahmoud https://orcid.org/0000-0003-3942-7370
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
- License Information
-
More Information
Article History
Received: 17 September 2025
Revised: 17 October 2025
Accepted: 11 November 2025
First Online: 5 December 2025
Competing interests
: AK, AS, TR, RM, EA, VR, MA declare no financial conflicts of interest. MI declares consultancy for US Sanofi, Bristol Myers Squibb and ADC therapeutics; HM declares consultancy or advisory board member: Bristol Myers Squibb, CRISPR Therapeutics, Incyte, Jazz Pharmaceuticals, Senti Bioscience, Autolus, Kite/Gilead, Sobi; medical monitor for Bone Marrow Transplant Clinical Trial Network; TN declares clinical trial research support to the institution from Novartis and Karyopharm; RP declares serving on the advisory board for Sanofi Aventis and Astra Zeneca, has received honoraria from Sanofi Aventis, Astra Zeneca and Beigene, and has received research funding from Bristol Myers Squibb Foundation, Beigene, Cullinan Therapeutics, and GlaxoSmithKline; MAK-D declares research/grant from Bristol Myers Squibb, Novartis, and Pharmacyclics and lecture/honoraria from Kite Pharma.
: All methods were performed in accordance with the relevant guidelines and regulations. The study selection process was summarized using the PRISMA flow diagram and methodology for conduct of systematic reviews followed the Cochrane Collaboration Handbook.
